Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Lindbrook Capital LLC

Lindbrook Capital LLC lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 37.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 369 shares of the biopharmaceutical company’s stock after purchasing an additional 100 shares during the period. Lindbrook Capital LLC’s holdings in Alnylam Pharmaceuticals were worth $71,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in ALNY. Quent Capital LLC lifted its stake in shares of Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares during the period. Anchor Investment Management LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $38,000. Acadian Asset Management LLC raised its position in Alnylam Pharmaceuticals by 52.4% during the third quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 311 shares during the period. Avitas Wealth Management LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $204,000. Finally, EP Wealth Advisors LLC raised its position in Alnylam Pharmaceuticals by 6.4% during the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 71 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 1.6 %

Shares of ALNY opened at $143.80 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $143.50 and a 12-month high of $218.88. The firm has a 50-day moving average price of $150.77 and a 200 day moving average price of $166.28. The firm has a market capitalization of $18.11 billion, a P/E ratio of -40.39 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to analysts’ expectations of $439.38 million. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the business earned ($1.68) EPS. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ALNY shares. BMO Capital Markets restated an “outperform” rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 27th. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Wolfe Research started coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They set a “peer perform” rating for the company. JPMorgan Chase & Co. upped their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a research report on Thursday, February 1st. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $165.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Nine research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $216.12.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.